Loading...

Home
ETF
COYA

COYA

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

COYA News

Coya Therapeutics Secures $11.1 Million in Private Placement

Jan 30 2026seekingalpha

Coya Therapeutics Secures $11.1 Million in Private Placement

Jan 30 2026Yahoo Finance

Coya Therapeutics Receives FDA IND Approval for COYA 302 to Treat Frontotemporal Dementia

Jan 05 2026Newsfilter

D. Boral Capital Reiterates Buy Rating for Coya Therapeutics with $15 Price Target Intact

Nov 12 2025Benzinga

Coya Therapeutics Reveals Pricing for Increased $20 Million Public Offering of Common Stock

Oct 24 2025Newsfilter

Coya Therapeutics Declines Following $20M Stock Offering Announcement

Oct 24 2025SeekingAlpha

Coya Therapeutics Unveils Plans for Public Offering of Common Stock

Oct 23 2025Newsfilter

David Einhorn's Greenlight Chooses This Small Biotech Over AI Hype

Oct 22 2025MarketWatch

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Sep 29 2025PRnewswire

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Sep 22 2025PRnewswire

D. Boral Capital Reiterates Buy Rating for Coya Therapeutics with $18 Price Target Intact

Sep 17 2025Benzinga

EXCLUSIVE: Coya Therapeutics' Investigational GLP-1 Combination Therapy Shows Promise for Alzheimer's Disease

Sep 16 2025Benzinga

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Sep 16 2025PRnewswire

Biotech Stocks Soar in After-Hours Trading: CAPR and TMDX Top the List Following Trial News and Earnings Boost

Sep 09 2025NASDAQ.COM

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

Sep 04 2025PRnewswire

PRISM MarketView Presents Exclusive Interview with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases with Treg Therapies

Sep 03 2025Newsfilter